Original Article

BioPATH: A Biomarker Study in Asian Patients with HER2+ Advanced Breast Cancer Treated with Lapatinib and Other Anti-HER2 Therapy

Sung-Bae Kim, MD, PhD1, In-Gu Do, MD, PhD2, Janice Tsang, MD3, Tae-You Kim, MD, PhD4, Yoon-Sim Yap, MBBS, FRACP, PhD5, Gerardo Cornelio, MD6, Gyungyub Gong, MD, PhD7, Soonmyung Paik, MD8, Suee Lee, MD, PhD9, Ting-Ying Ng, MD10 Sarah Park, MD11, Ho-Suk Oh, MD, PhD12, Joanne Chiu, MBBS3, Joohyuk Sohn, MD, PhD13, Moonhee Lee, MD, PhD14, Young-Jin Choi, MD, PhD15, Eun Mi Lee, MD16, Kyong-Hwa Park, MD, PhD17, Christos Nathaniel, PhD18, Jungsil Ro, MD, PhD19

Sung-Bae Kim and In-Gu Do contributed equally to this work.

Running Title: Biomarker Study in Asian Patients with HER2+ ABC

*Preliminary data was presented previously: Kim SB et al. HER2-related biomarkers in HER2+ breast cancer patients in Asia Pacific. Presented at: San Antonio Breast Cancer Symposium; December 10-14, 2013; San Antonio, TX, USA (Poster P4-12-28).

Correspondence: Jungsil Ro, MD, PhD
Center for Breast Cancer, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-1680 Fax: 82-31-920-0450 Email: jungsro@ncc.re.kr

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi:10.4143/crt.2018.598
1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, 3Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China, 4Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, 5Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 6Department of Medicine, San Juan De Dios Hospital, Manila, Philippines, 7Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 8Severance Biomedical Research Institute, Yonsei University College of Medicine, Seoul, 9Department of Internal Medicine, Dong-A University Hospital, Busan, Korea, 10Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, China, 11The Center for Anti-Cancer Companion Diagnostics, Bio-MAX/N-Bio, Seoul National University, Seoul, 12Department of Hematology-Oncology, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, 13Division of Medical Oncology, Yonsei Cancer Center, Seoul, 14Division of Hematology-Oncology, Inha University Hospital, Incheon, 15Department of Hematology-Oncology, Pusan National University Hospital, Busan, 16Department of Internal Medicine, Kosin University Gospel Hospital, Busan, 17Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea, 18Novartis Pharmaceuticals Corporation, APSA, Midrand, South Africa, 19Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea
Abstract

Purpose

BioPATH is a non-interventional study evaluating the relationship of molecular biomarkers (PTEN deletion/downregulation, \textit{PIK3CA} mutation, truncated HER2 receptor \([p95HER2]\), and tumor \textit{HER2} mRNA levels) to treatment responses in Asian patients with HER2+ advanced breast cancer treated with lapatinib and other HER2-targeted agents.

Materials and Methods

Female Asian HER2+ breast cancer patients (n=154) who were candidates for lapatinib-based treatment following metastasis and having an available primary tumor biopsy specimen were included. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, overall survival on lapatinib, correlation between biomarker status and PFS for any previous trastuzumab-based treatment, and conversion/conservation rates of the biomarker status between tissue samples collected at primary diagnosis and at recurrence/metastasis. Potential relationships between tumor mRNA levels of HER2 and response to lapatinib-based therapy were also explored.

Results

p95HER2, PTEN deletion/downregulation and \textit{PIK3CA} mutation did not demonstrate any significant co-occurrence pattern and were not predictive of clinical outcomes on either lapatinib-based treatment or any previous trastuzumab-based therapy in the metastatic setting. Proportions of tumors positive for p95HER2 expression, \textit{PIK3CA} mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2%, and 56.2%, respectively. Despite limited availability of paired samples, biomarker status patterns were conserved in most samples. \textit{HER2} mRNA levels were not predictive of PFS on lapatinib.
Conclusion

The prevalence of p95HER2 expression, \textit{PIK3CA} mutation, and PTEN deletion/downregulation at primary diagnosis were similar to previous reports. Importantly, no difference was observed in clinical outcome based on the status of these biomarkers, consistent with reports from other studies.

Key words

Biomarkers, Breast neoplasms, HER2, Lapatinib, Trastuzumab
Introduction

In recent years breast cancer has become an emerging health issue for Asian women [1-4]. Effective population-based treatment planning and monitoring may reduce the rising concern and burden of breast cancer in Asia. Overexpression of human epidermal growth factor receptor 2 (HER2) has been observed in 15% to 20% of invasive breast cancers and is recognized to be a driving force of tumor biology [5]. Therapeutic strategies to block the HER2 signaling pathway include monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKI). In context of recent developments in our understanding of drug resistance mechanisms of breast cancer, there is a continuous effort to develop new effective therapies.

Trastuzumab is a standard treatment for HER2-positive (HER2+) breast cancer in both adjuvant and advanced settings. Clinical studies have demonstrated significantly prolonged time to disease progression, a higher rate of objective response, a longer duration of response, and increased survival when trastuzumab is added to chemotherapy in patients with previously untreated metastatic breast cancer (MBC) [6]. Furthermore, the addition of trastuzumab to chemotherapy significantly improved clinical outcome in patients in multiple clinical trials in the early and locally advanced settings [7-10]. Since the development of trastuzumab, advancements in HER2–targeting therapies have led to approval of three additional agents in the metastatic setting—pertuzumab, trastuzumab emtansine (T-DM1), and lapatinib. Key recommendations for first-line treatment of HER2+ advanced breast cancer (ABC) or MBC include combination of HER2 inhibitors trastuzumab and pertuzumab with a taxane (preferred) regardless of prior adjuvant trastuzumab, alone or with chemotherapy. T-DM1 (preferred approach) or other anti-HER2 treatments in combination with chemotherapy are recommended treatment options in the second line and beyond [11-13].
Lapatinib, a TKI targeting epidermal growth factor receptor and HER2, significantly prolonged time to progression in combination with capecitabine versus capecitabine alone in patients whose metastatic tumors were progressing on trastuzumab-based chemotherapy [14]. Lapatinib has also demonstrated significant clinical benefit in Asian patients with HER2+ ABC. A study primarily conducted in Asian patients (86%) demonstrated that lapatinib plus paclitaxel offers a significantly improved overall survival (OS), progression-free survival (PFS), and overall response rate over paclitaxel alone in patients with HER2+ MBC [15]. Lapatinib plus capecitabine was well tolerated in Japanese patients with HER2+ ABC or MBC who had progressed on trastuzumab [16]. Results from 2 independent studies confirmed that the combination of lapatinib and capecitabine is an effective and well-tolerated treatment option in a population of Chinese women with HER2+ ABC or MBC who have had disease progression following other treatments [17, 18]. Currently, lapatinib-based therapy is approved in several countries for the treatment of HER2+ ABC that progressed on treatment regimens containing an anthracycline, a taxane, and trastuzumab.

*De novo* and acquired resistance to HER2–directed approaches remains a clinical challenge. Despite advances in the management of metastatic HER2+ breast cancer, the response rate (RR) in the first-line anti-HER2 therapy setting ranges from 50% to 80%, and from only 20% to 40% in the second-line setting [6, 14, 19-22]. Many single-gene molecular markers have been evaluated as predictors of response to specific regimens; however, reliable molecular predictors for efficacy of anti-HER2 therapies are lacking. A number of reports suggest presence of amino-terminally-truncated HER2 (p95HER2) [23, 24] *PI3KCA* somatic mutations [25], deletion/down-regulation of the phosphatase and tensin homolog (PTEN) gene [26], and tumor *HER2* mRNA levels [27, 28] as potential markers of response or resistance to anti-HER2 therapy. Altered expression of p95HER2, *PI3KCA*, and PTEN is
associated with impaired efficacy of trastuzumab and/or pertuzumab therapy in MBC [23, 29-31], although T-DM1 has been reported to be effective in both wild-type and \textit{PIK3CA}-mutated tumors [32]. In Japanese patients with breast cancer receiving lapatinib monotherapy after trastuzumab-based therapies, biomarker analyses suggest clinical benefit in patients with tumors harboring \textit{PIK3CA} mutation or low expression of PTEN [33, 34]. Further research into these biomarkers may provide valuable insights into their reliability to predict the success or failure of specific anti-HER2 treatment strategies. Moreover, the availability of predictive biomarkers may help to guide a more cost-effective and rational use of anti-cancer drugs.

Tumors harboring p95HER2 are potential targets for lapatinib therapy because of lapatinib’s ability to bind to the adenosine triphosphate binding site in the intracellular kinase domain of HER2; in contrast, trastuzumab binds an extracellular epitope on HER2, which is absent from truncated p95HER2. In a previous report [25], tumor progression was more likely among trastuzumab-treated subjects with \textit{PIK3CA} mutations than those without. Interestingly, some biomarker studies suggested that lapatinib may have benefit in tumors that have achieved some level of escape from HER2 dependence through \textit{PIK3CA} mutation [33, 34]. Clinical efficacy of trastuzumab but not lapatinib was impaired in tumors with PTEN downregulation/deletion [35]. Thus all three biomarkers have the potential to be predictive of lapatinib’s clinical utility in ABC. Limited availability of biomarker studies for lapatinib constrains our ability to predict the success or failure of lapatinib-based regimens for treatment of patients with HER2+ ABC.

This non-interventional study investigated the frequency of biomarkers, including p95HER2 expression, PTEN deletion/down-regulation, and \textit{PIK3CA} mutation, in addition to HER2 mRNA levels in lapatinib-treated and/or trastuzumab-treated patients with breast cancer, and their use as predictive markers in the HER2 treatment paradigm.
Materials and Methods

1. Study design

BioPATH is an international multicenter, observational study designed to investigate the frequency of biomarkers, including p95HER2 expression, PTEN deletion/down-regulation, and PIK3CA mutation, in female patients with HER2+ ABC treated with lapatinib-based therapy. Patients were included who received other HER2-targeted agents before study entry. Biomarker status was quantified in the analysis population, and possible relationships between biomarkers and outcomes, adjusting for other clinical and pathological factors, were measured. Patients were enrolled in 17 centers in five countries (Hong Kong, Korea, Malaysia, the Philippines, and Singapore). Data from the single center in Malaysia could not be verified, following the death of the principal investigator, and was not included (n=2). The local ethics review boards approved the protocol, and all patients gave written informed consent before study enrollment. Patients continued with their regular treatment during the study and no treatment interventions were made.

2. Study endpoints

The primary endpoint was PFS, defined as time (in weeks) from initiation of the first lapatinib-based regimen given in the metastatic setting to disease progression from that regimen or death from any cause. The correlation of p95HER2 expression, PTEN deletion/down-regulation, and PIK3CA mutation, individually and in combination, with PFS following lapatinib-based treatment. Secondary endpoints were RR and OS among females initiated on the lapatinib-based regimen, biomarker levels and their association with PFS on previous trastuzumab-based treatment in the metastatic setting (defined as time from initiation of the first trastuzumab-based regimen given in the metastatic setting to disease progression.
from that regimen or death from any cause), and biomarker conservation/conversion rates. The RR was defined as percentage of patients showing complete response (CR) or partial response (PR) to lapatinib-based treatment, based on physician’s clinical judgment. The OS was defined as time (in weeks) from initiation of the first lapatinib-based regimen until death due to any cause. For patients who were alive at the end of study or lost to follow-up, time to death was censored at the time of last contact. Biomarker conversion/conservation rates between primary diagnosis and at recurrence/metastasis stratified according to the treatment received before the re-biopsy were explored for paired samples. Exploratory analyses were performed to investigate potential relationships between HER2 tumor mRNA levels and response to lapatinib-based therapy. All enrolled patients were followed until death, loss to follow-up, or until data cutoff date, whichever came first. During the study, patients were managed as per physician’s standard medical care.

3. Patients

Female patients with confirmed HER2+ metastatic/recurrent breast cancer who were exposed to ≤2 lines of trastuzumab-based regimens in the metastatic setting prior to start of lapatinib-based regimen were eligible for this study. Patients who received systemic treatment for either early-stage or recurrent/metastatic disease were eligible for enrollment. Patients needed to have a historical tumor biopsy specimen available from their primary breast cancer diagnosis, or at least an available specimen from the period before starting any anti-HER2 therapy. Prior exposure to other anti-HER2 therapies (eg, pertuzumab, T-DM1, neratinib, ertumaxomab, AV-412, BIBW2992, CUDC-101, and anti-HER2 vaccines) except trastuzumab was not allowed. Patients with primary lesions that were not of breast origin were also excluded.
4. Assessment

We performed biomarker analysis on p95HER2, PI3KCA, and PTEN to explore associations of these markers with clinical outcomes on either lapatinib-based or trastuzumab-based therapy in the metastatic setting. p95HER2, PTEN, and PIK3CA biomarker assays were performed at a central laboratory (Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea) on sections from formalin-fixed, paraffin-embedded (FFPE) tumor blocks. p95HER2 expression was initially evaluated by immunohistochemistry (IHC) assay (by bioMérieux, but was later changed to the VeraTag quantitative assay technology for determining p95HER2 expression (Monogram Biosciences, South San Francisco, CA) [36]. An IHC 3+ result was considered as HER2+. PTEN was assayed by IHC using a PTEN antibody (clone Y184, Abcam, Cambridge, UK) on a Dako Autostainer system (Dako, Glostrup, Denmark). The Sequenom MassARRAY platform (Sequenom, San Diego, CA, USA) was used to detect the presence of PIK3CA somatic mutations; samples were classified as positive or negative for PIK3CA mutations based on their presence or absence. For determining mRNA levels of HER2, total RNA extracted from FFPE tumor samples was assayed on the nCounter platform (NanoString Technologies, Seattle, WA) using the nCounter Virtual Breast Cancer Estrogen Receptor Gene probe set comprising 196 breast cancer and estrogen receptor signaling pathway test genes and 6 internal reference genes.

5. Statistical analysis

Preplanned statistical analyses were performed on the analysis population, defined as patients who met all eligibility criteria and had available data for at least one of the 3 biomarkers, using PASW Statistics ver. 18 (SPSS Inc., Chicago, IL). A sample size of 500 patients was originally planned. For the primary objective, sample size calculations were
based on the precision of the estimated prevalence of the 3 biomarkers (presence/absence of p95HER2 protein expression, PTEN deletion/down-regulation, and PIK3CA mutation). The sample size had to provide enough biomarker-positive patients for the confidence intervals (CIs) to be sufficiently narrow. Using the large-sample normal approximation, a sample size of 500 would ensure that a 2-sided 90% CI for the p95HER2-positive rate would extend ≤0.04 from the observed proportion. The sample size was further refined using power analysis because the primary objective included hazard ratio estimation. At the 5% significance level and with 90% power, 68 progression or death events were needed to detect a hazard ratio of ≤0.45 (biomarker-positive group relative to negative group). All statistical tests were 2-sided unless otherwise specified.

PFS lapatinib-based treatment or trastuzumab-based treatment was analyzed for the overall study population and for subgroups based on positive and negative biomarker status. Survival times and PFS-prognostic factor relationship were estimated using the Kaplan-Meier product-limit method and compared across subgroups using log-rank tests. Response rate was measured as the proportion of patients showing either CR or PR to lapatinib-based treatment received post study entry. For OS, survival outcomes were determined based on patient status at data cutoff (alive, deceased, or unknown; time to death was censored at the time of last contact for patients who were alive at the end of study or lost to follow-up), and analyzed using the Kaplan-Meier method.

Distributions of the 3 biomarkers were summarized using counts and percentages of patients who were positive or negative for p95HER2 expression, PTEN deletion/down-regulation, and PIK3CA mutation at primary diagnosis, and at recurrence/metastasis, where available. A chi-square test, or a Fisher exact test for small frequency counts, was used to test for statistically significant associations among the three biomarkers. Multivariate Cox
proportional hazards models were used to evaluate associations between status of the three biomarkers and PFS, on either lapatinib or trastuzumab after adjusting for relevant prognostic factors. No multiplicity adjustment was performed to control for type I error. In addition to the expression levels of the three biomarkers, other prognostic factors assessed for PFS with lapatinib-based treatment were HER2 fluorescence in situ hybridization-positivity at primary diagnosis and IHC 2+ status at study entry. Prognostic factors analyzed for PFS with trastuzumab-based treatment included ethnic group and recurrence in the contralateral breast at study entry.

Conversion and conservation rates for the three biomarkers between primary diagnosis and recurrence/metastasis were determined by cross-tabulating data for patients with conservation or conversion (negative to positive or vice versa) of biomarker status. Associations between tumor mRNA markers and PFS on lapatinib-based treatment were evaluated using the Kaplan-Meier method. The differences in PFS between subgroups based on mRNA marker status were tested using the log-rank test.

6. Ethical statement

This study was performed in compliance with Good Clinical Practices and GlaxoSmithKline Standard Operating Procedures for all processes involved, including the archiving of essential documents. This study complies with US 21 CFR 312.120, as described in the Ethics and Good Clinical Practice section. This study was conducted in accordance with the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice (GCP) and applicable country-specific requirements, all applicable subject privacy requirements, and the ethical principles outlined in the Declaration of Helsinki 2008. The study was monitored in
accordance with ICH E6, Section 5.18.

The protocol, any amendments, the informed consent form, and other information that required pre-approval were reviewed and approved by the respective investigational center ethics committees and institutional review boards (IRBs), in accordance with the International Conference on Harmonization (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice (GCP) and applicable country-specific requirements. Ethics committee and IRB approvals were maintained in the Sponsor’s study file.

This study was conducted in accordance with ICH GCP and all applicable subject privacy requirements, and, the ethical principles outlined in the Declaration of Helsinki 2008. The study was monitored in accordance with ICH E6, Section 5.18.

Investigators were trained to conduct the study in accordance with GCPs and the protocol as defined in ICH E3, Section 9.6. Written commitments were obtained from investigators to comply with GCP and to conduct the study in accordance with the protocol.

Written informed consent was obtained from each subject prior to the performance of any study-specific procedures. The investigator provided the subject with as much time as necessary to review the document, to inquire about details of the study, and to decide whether or not to participate in the study. The informed consent was signed and dated by the study subject and by the person who conducted the informed consent discussion. Case report forms (CRFs) were provided for each subject’s data to be recorded.
Results

1. Patient demographics and disease characteristics

This study enrolled patients initiating lapatinib-based treatment for metastatic disease between August 2010 and December 2012. Of the enrolled 156 eligible patients, data for 154 were analyzed. Two patients from a single center in Malaysia were not included in the analysis because patient data could not be verified following the death of the principal investigator at that center. The median age of patients at primary diagnosis was 52.9 years and the median time between primary diagnosis and study entry was 3.3 years (Table 1). Most patients were either Korean (71.4%) or Chinese (26.0%). Biopsy or tumor resection was performed for all 154 patients in the analysis population at the time of primary diagnosis. At primary diagnosis, most patients (76.7%) had stages I to III, and 22.1% had de novo stage IV disease; nearly all (97.4%) had MBC by study entry. Invasive ductal carcinoma was the most common histology at primary diagnosis (96.8%). Of the 154 patients in the analysis population, 147 (95.5%) were positive for HER2 at primary diagnosis, with five not determined (3.2%) and two negative (1.3%) (Table 1). At study entry, HER2 status was not determined for the majority of patients (n=109, 70.8%); however, all who did (n=45: 29.2%) were HER2+ (Table 1). The majority of samples available for biomarker analyses were from the primary tumor, and biomarker data from matched primary/metastasis samples were available in <15% of patients.

Prior to study entry, 24 patients received adjuvant systemic treatment for early-stage disease, 89 received treatment in adjuvant and recurrent/metastatic disease settings, and 42 received for recurrent/metastatic disease only. Trastuzumab (67.4%) and taxanes (65.9%) were the most common agents in first-line regimens in the metastatic setting prior to study entry, followed by hormonal therapy (14.7%) and anthracyclines (10.9%); 27.1% received
other chemotherapy. At study entry, 97% (72 of 74 patients) of first- and second-line regimens contained lapatinib, with or without other chemotherapy agents (Table 2).

2. Clinical outcomes

Median PFS with lapatinib-based regimens in the full study population was 33.3 weeks (95% CI, 26.1 to 40.5 weeks) (Fig. 1A). The RR (CR + PR) for lapatinib-based regimens was 16.9% (Table 3). Median OS with lapatinib-based regimens was 110.7 weeks (95% CI, 87.4 to 134.0 weeks) for the analysis population. At data cut-off (Aug 31, 2013), 70 patients had died (45.5%), 59 were alive (38.3%), and 25 were lost to follow-up (16.2%). Most deaths were attributed to disease progression (n=63, 90.0%). Incidence of new brain metastases after study entry was 20%.

3. Biomarker analyses for lapatinib treatment

Core biomarkers p95HER2, PTEN, and PIK3CA and exploratory marker HER2 mRNA level were evaluated for their correlation with clinical responsiveness to lapatinib-based treatment in the metastatic setting. In the analysis population, there were no significant associations between the three biomarkers (p95HER2, PTEN, PIK3CA) and PFS with lapatinib-based treatment. Biomarker-based subgroups showed similar median PFS with substantially overlapping CIs (Fig. 1B-D). No statistically significant associations between RR and the status of the 3 biomarkers were observed (data not shown). Median OS with lapatinib-based treatment also was not significantly different for biomarker-positive and biomarker-negative groups. Multivariate Cox regression analyses showed no significant associations between any of the three biomarkers and PFS or OS with lapatinib-based treatment, with or without adjustment for prognostic factors. Exploratory univariate analyses
CANCER RESEARCH AND TREATMENT (CRT)

showed no significant associations of HER2 mRNA levels and PFS with lapatinib-based treatment (data not shown).

4. Biomarker analysis for other prior trastuzumab treatment

Analysis of biomarker and covariate correlation with clinical response to previous trastuzumab-based treatment demonstrated no statistically significant correlations among the three biomarkers (p95HER2, PTEN, PIK3CA) at primary diagnosis. Trastuzumab (67.4%) was the most common systemic agent in first-line regimens prior to study entry. Median PFS from initiation of the first-line trastuzumab-based regimen in the metastatic setting was 63.0 weeks (95% CI, 53.6 to 72.4 weeks) (Fig. 2A). Progression-free survival with previous trastuzumab-based treatment in the metastatic setting had no statistically significant association with any of the three biomarkers. Accordingly, median PFS was similar in biomarker-positive and biomarker-negative subgroups (Fig. 2B-D). Multivariate analyses demonstrated that, of the prognostic factors tested, ethnic group and recurrence in the contralateral breast at study entry were the only potential prognostic factors associated with PFS with trastuzumab-based treatment; the strongest potential factor was Korean ethnicity (Table 4), possibly reflecting regional variations in treatment practices. Results from the multivariate analysis should however be interpreted cautiously as adjusted hazard ratios did not reach statistical significance at nominal p-value of 0.05.

5. Conservation/conversion rates

Biomarker analyses demonstrated that the proportion of tumors positive for p95HER2 expression, PIK3CA mutation, and PTEN deletion/down-regulation at primary diagnosis were 32%, 31.2% and 56.2%, respectively (Fig. 3). For patients with available tumor samples from
primary diagnosis and re-biopsy, biomarker status remained 100% conserved for p95HER2 and mostly unchanged for PIK3CA (84.2%). Conversely biomarker status was 62.5% conserved for PTEN (Fig. 4). However, the number of paired samples available for this analysis was very small (fewer than 20 for all 3 biomarkers), and these results should be interpreted with caution.

Discussion

Personalized cancer medicine based on molecular characteristics of a tumor from an individual patient and validated biomarkers with acceptable sensitivity and specificity has great potential in the therapy of many types of cancer [37]. Recent studies have identified tumor-infiltrating lymphocytes [38], genetic signatures [39], and HR status [40] as potential biomarkers for response to trastuzumab-based treatment. Limited understanding of biomarker profiles that can reliably predict response to lapatinib-based treatment prompted us to investigate biomarker profiles of p95HER2, PTEN, PIK3CA, and tumor HER2 mRNA levels in a population of lapatinib-treated HER2+ MBC patients from four Asian countries, many of whom were previously treated with trastuzumab-based therapy. Our study shows that p95HER2, PTEN, and PIK3CA biomarker status was not predictive of PFS on either lapatinib-based or trastuzumab-based therapy in the metastatic setting. The status of the three biomarkers also was not predictive for CR, PR, or OS with lapatinib-based regimens. These results are in accordance with recent data for lapatinib-based treatment in relation to p95HER2 status in Korean patients [41], and to PIK3CA status in Chinese patients [17]. Our study did not reveal any PFS differences with trastuzumab-based treatment between PIK3CA WT and mutated subgroups, possibly because of the small sample size. However, PFS was
shorter in patients with \textit{PIK3CA} mutations in the CLEOPATRA trial [31].

\textit{PIK3CA} mutations have been associated with less response to chemotherapy and the combination of chemotherapy and HER2-targeted agents in several neoadjuvant trials [42]. However, these results do not indicate a direct link between \textit{PIK3CA} mutation status and response to HER2-targeted agents because patients received chemotherapy concomitantly. Randomized trials in the adjuvant setting have reported that alterations in \textit{PIK3CA} or PTEN do not predict trastuzumab resistance [43, 44]. In addition, several reports have demonstrated lack of association between \textit{PIK3CA} mutations or PTEN loss, and the efficacy of lapatinib, regardless of whether administered alone or in combination with chemotherapy [34, 35, 45, 46]. Moreover, patients with HER2-overexpressing inflammatory breast cancers responded to lapatinib monotherapy regardless of PTEN status [47]. Thus the predictive performance of the three biomarkers, p95HER2, PTEN, and \textit{PIK3CA} in our analysis mirrors results from other global studies. Furthermore, we show that PFS with lapatinib-based treatment in Asian patients is consistent with that reported previously in real-world settings [17, 48-50]. In the GeparQuattro study, response to trastuzumab-based therapy was found to correlate with \textit{HER2} mRNA levels only in patients with estrogen receptor-positive tumors [28]. Similarly, in the analogous, albeit smaller, trastuzumab arm of the NeoALTTO study, HER2 protein expression trended toward a correlation with pathologic complete response (pCR) in the hormone receptor-positive group, but there was no relationship between HER2 and pCR in the hormone receptor-negative group [51]. However \textit{HER2} tumor mRNA levels were not predictive of PFS on lapatinib-based treatment in our study.

In our study p95HER2 expression and PTEN deletion/down-regulation at primary diagnosis were 32%, and 56.2%, respectively, consistent with earlier reports wherein the frequency of p95HER2 expression was approximately 30% in HER2+ tumors [52, 53] and
approximately 50% were PTEN-deficient [54]. Furthermore, the frequency of PIK3CA mutation was 39% in an array of HER2+ primary breast cancers [55], akin to the 31% PIK3CA mutation frequency at primary diagnosis in our study. Importantly, although a number of different methods were used to measure individual biomarkers across these studies and no standard validated method exists thus far, the results are very similar overall.

Although performed in a largely Asian patient population, mostly of Korean and Chinese ethnicity, with HER2+ ABC, our results are consistent with global studies. Thus, our results are not likely to be biased or population-specific, and may have relevance for other HER2+ patients with biomarker profiles of interest within the general breast cancer population. Interestingly, we found that incidence of new brain metastases after study entry was approximately 20%, somewhat lower than the 25% to 36% range reported in previous studies of trastuzumab-based treatment in HER2+ breast cancer patients [48-50, 56]. This is potentially encouraging in light of reports that lapatinib-capecitabine [57-59] and lapatinib-trastuzumab [60] combinations may provide clinical benefit in patients with MBC with brain metastases.

Our study was limited by tissue availability, repeat biopsies at metastasis in only 19 patients, and slow patient recruitment, which resulted in a substantially smaller analysis population (n=154) than originally planned (n=500). As can be expected in a non-interventional study, there was no randomization for treatment assignment, which differs from biomarker analyses from randomized trials such as NeoALTTO and GeparQuattro. Results from the analysis of biomarker conservation/conversion patterns in our study should be interpreted carefully, keeping in mind the limited availability of paired samples. Finally, as our study allowed retrospective enrollment, precision of survival estimates may have been reduced because of unavailability of medical record information (eg, dates of disease
progression or death) for some of these patients.

In conclusion, our study did not demonstrate any significant correlation between biomarker status of p95HER2, PTEN deletion/downregulation, PI3KCA mutation or HER2 mRNA levels and clinical outcome on lapatinib-based treatment in the enrolled cohort of HER2+ ABC patients, similar to previous reports. Additionally, median PFS on lapatinib-based treatment in our study was similar to that observed in previous studies of lapatinib-based treatment in ABC/MBC [17, 48-50]. Predictive biomarkers can facilitate the identification and establishment of individualized treatment for patients with HER2+ ABC. The correlations between biomarkers and response/resistance to lapatinib-based treatment have not been fully delineated thus far. Hence, additional studies are needed to better identify patient populations likely to benefit from lapatinib-based treatment for HER2+ ABC.
Conflicts of Interest

Sung-Bae Kim has received funding from Novartis, Sanofi Aventis, Kyowa Kirin Inc., Dongkook Pharmaceuticals Company Ltd. Gerardo Cornelio has received funding from Renovo; has served as a consultant/advisory role for Astra Zeneca Oncology, BF, MSD Oncology, and Esai Oncology. Yoon Sim Yap has served as a consultant/advisory role from Novartis. Soonmyung Paik has received funding from GSK for this study; has served as a consultant/advisory role for Leica Biosystems. Christos Nathaniel is an employee of Novartis Pharmaceuticals Corporation. The following authors have nothing to disclose: In-Gu Do, Janice Tsang, Tae-You Kim, Gyungyub Gong, Suee Lee, Ting-Ying Ng, Sarah Park, Ho-Suk Oh, Joanne Chiu, Joohyuk Sohn, Moonhee Lee, Young-Jin Choi, Eun Mi Lee, Kyong-Hwa Park, and Jungsil Ro.

Acknowledgments

This study was sponsored by GlaxoSmithKline. Lapatinib is an asset of Novartis Pharmaceuticals Corporation as of March 2, 2015. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank the pathologists for their work analyzing the tumor samples for this manuscript: Hee Jin Lee. We thank Maupali Dasgupta, PhD, ProEd Communications, Inc., for her medical editorial assistance with this manuscript.
References


This article is protected by copyright. All rights reserved.


Table 1. Patient demographics and baseline disease characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=154)</td>
</tr>
<tr>
<td>Age distribution at primary diagnosis (yr)</td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>48.1±9.8</td>
</tr>
<tr>
<td>Median (range)</td>
<td>52.9 (24.8-76.5)</td>
</tr>
<tr>
<td>&lt; 50 yr vs. ≥ 50 yr</td>
<td>85 (55.2):69 (44.8)</td>
</tr>
<tr>
<td>Age distribution at study entry (yr)</td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>52.4±9.9</td>
</tr>
<tr>
<td>Median (range)</td>
<td>48.7 (28.3, 86.0)</td>
</tr>
<tr>
<td>&lt; 50 yr vs. ≥ 50 yr</td>
<td>62 (40.3): 92 (59.7)</td>
</tr>
<tr>
<td>Time between primary diagnosis and study entry (yr)</td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>4.3±3.2</td>
</tr>
<tr>
<td>Median (range)</td>
<td>3.3 (0.2-19.9)</td>
</tr>
<tr>
<td>Postmenopausal</td>
<td></td>
</tr>
<tr>
<td>At primary diagnosis</td>
<td>78 (50.6)</td>
</tr>
<tr>
<td>At study entry</td>
<td>131 (85.1)</td>
</tr>
<tr>
<td>ECOG PS</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>42 (27.3)</td>
</tr>
<tr>
<td>1</td>
<td>107 (69.5)</td>
</tr>
<tr>
<td>2</td>
<td>5 (3.2)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Korean</td>
<td>110 (71.4)</td>
</tr>
<tr>
<td>Chinese</td>
<td>40 (26.0)</td>
</tr>
<tr>
<td>Filipino</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Malay</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Cancer stage(s)&lt;sup&gt;a&lt;/sup&gt;)</td>
<td></td>
</tr>
<tr>
<td>At primary diagnosis</td>
<td></td>
</tr>
<tr>
<td>I, II, or III</td>
<td>118 (76.7)</td>
</tr>
<tr>
<td>IV (de novo)</td>
<td>34 (22.1)</td>
</tr>
<tr>
<td>Unknown</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>At study entry&lt;sup&gt;b&lt;/sup&gt;)</td>
<td></td>
</tr>
<tr>
<td>I, II, or III (metastatic)</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>IV (de novo)</td>
<td>150 (97.4)</td>
</tr>
<tr>
<td>Unknown</td>
<td>0</td>
</tr>
<tr>
<td>HER2 status</td>
<td></td>
</tr>
<tr>
<td>At primary diagnosis</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>147 (95.5)</td>
</tr>
<tr>
<td>Negative</td>
<td>2 (1.3)</td>
</tr>
<tr>
<td>Not performed</td>
<td>5 (3.2)</td>
</tr>
<tr>
<td>At study entry</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>45 (29.2)</td>
</tr>
</tbody>
</table>

<sup>a</sup> At primary diagnosis
<sup>b</sup> At study entry

Korean Cancer Association
This article is protected by copyright. All rights reserved.
### ER status

#### At primary diagnosis
- **Positive**: 65 (42.2)
- **Negative**: 85 (55.2)
- **Unknown**: 4 (2.6)

#### At study entry
- **Positive**: 20 (13.0)
- **Negative**: 22 (14.3)
- **Unknown**: 112 (72.7)

SD, standard deviation; ECOG PS, Eastern Cooperative Oncology Group performance status; HER2, human epidermal growth factor receptor 2; ER, estrogen receptor.  

*According to the American Joint Committee on Cancer 7th edition,  
Data were not recorded for all patients.*
Table 2. Agents used in systemic therapy regimens

<table>
<thead>
<tr>
<th>Regimen number&lt;sup&gt;a)&lt;/sup&gt;</th>
<th>Trastuzumab</th>
<th>Lapatinib</th>
<th>Taxane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior to study entry&lt;sup&gt;b)&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (adjuvant; n=129)</td>
<td>87 (67.4)</td>
<td>2 (1.6)</td>
<td>85 (65.9)</td>
</tr>
<tr>
<td>2 (metastatic first-line; n=82)</td>
<td>22 (26.8)</td>
<td>9 (11.0)</td>
<td>16 (19.5)</td>
</tr>
<tr>
<td>≥3 (metastatic second-line or greater; n=100)</td>
<td>14 (14.0)</td>
<td>25 (25.0)</td>
<td>11 (11.0)</td>
</tr>
<tr>
<td>After study entry&lt;sup&gt;c)&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 (n=24)</td>
<td>0</td>
<td>24 (100)</td>
<td>1 (4.2)</td>
</tr>
<tr>
<td>2 (n=50)</td>
<td>0</td>
<td>48 (96.0)</td>
<td>0</td>
</tr>
<tr>
<td>≥3 (n=103)</td>
<td>17 (16.5)</td>
<td>65 (63.1)</td>
<td>5 (4.9)</td>
</tr>
</tbody>
</table>

<sup>a</sup>Systemic therapy for recurrent/metastatic disease, <sup>b</sup>Data was only available for 153 patients prior to study entry because 1 in the analysis population did not have data, <sup>c</sup>Data was only available for 138 patients after study entry because 16 in the analysis population did not have data. Other therapies not reported include anthracyclines, hormonal therapy and other chemotherapy and targeted therapy.
Table 3. RR with lapatinib-based regimens

<table>
<thead>
<tr>
<th>Response</th>
<th>No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CR</td>
<td>6 (3.9)</td>
</tr>
<tr>
<td>PR</td>
<td>20 (13.0)</td>
</tr>
<tr>
<td>Stable disease</td>
<td>26 (16.9)</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>86 (55.8)</td>
</tr>
<tr>
<td>Unable to determine</td>
<td>16 (10.4)</td>
</tr>
<tr>
<td>Total</td>
<td>154 (100)</td>
</tr>
<tr>
<td>RR</td>
<td>26 (16.9)(^a)</td>
</tr>
</tbody>
</table>

RR, response rate; CR, complete response; PR, partial response.
\(^a\)Patients with CR or PR.
Table 4. Potential prognostic factors affecting PFS with trastuzumab

<table>
<thead>
<tr>
<th></th>
<th>Unadjusted HR (95% CI) a)</th>
<th>p-value b)</th>
<th>Adjusted HR (95% CI)</th>
<th>p-value c)</th>
</tr>
</thead>
<tbody>
<tr>
<td>p95HER2 expression</td>
<td>0.85 (0.44-1.60)</td>
<td>0.628</td>
<td>1.01 (0.45-2.2)</td>
<td>0.975</td>
</tr>
<tr>
<td>PTEN deletion/down-regulation</td>
<td>0.84 (0.53-1.30)</td>
<td>0.456</td>
<td>1.30 (0.60-3.0)</td>
<td>0.488</td>
</tr>
<tr>
<td>PIK3CA mutation</td>
<td>1.20 (0.75-1.90)</td>
<td>0.476</td>
<td>1.20 (0.5-2.70)</td>
<td>0.649</td>
</tr>
<tr>
<td>Ethnic group: Malay d)</td>
<td>2.90 (0.70-12.70)</td>
<td>0.149</td>
<td>3.70 (0.70-19.80)</td>
<td>0.121</td>
</tr>
<tr>
<td>Ethnic group: Korean d)</td>
<td>2.10 (1.30-3.50)</td>
<td>0.004</td>
<td>2.00 (0.99-4.10)</td>
<td>0.051</td>
</tr>
<tr>
<td>Contralateral breast</td>
<td>0.37 (0.14-0.99)</td>
<td>0.047</td>
<td>0.30 (0.08-1.10)</td>
<td>0.078</td>
</tr>
</tbody>
</table>

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; p95HER2, truncated human epidermal growth factor receptor 2; PTEN, phosphatase and tensin homolog; PIK3CA, phosphatidylinositol 3 kinase (catalytic subunit). a)Univariate analysis, b)Log-rank test of survival distribution equality for subgroups defined by positive and negative biomarker status, c)From Cox proportional hazards model adjusted for prognostic factors that are found to be significantly related to PFS on lapatinib in the univariable analysis for primary endpoint and 3 biomarkers (p95HER2 protein expression, PTEN deletion/downregulation, and PIK3CA mutation), d)Reference group: Chinese.
Fig. 1. Progression-free survival (PFS) with lapatinib based regimens for all patients and biomarker subgroups. (A) All patients. (B) Patients with p95HER2 expression. (C) Patients with PTEN deletion/down-regulation. (D) Patients with PIK3CA mutation. Note: Log-rank test of survival distribution equality for subgroups was defined by positive and negative biomarker status. CI, confidence interval.
Fig. 2. Progression-free survival (PFS) with trastuzumab based regimens for all patients and biomarker subgroups. (A) All patients. (B) Patients with p95HER2 expression. (C) Patients with PTEN deletion/down-regulation. (D) Patients with PIK3CA mutation. Note: Log-rank test of survival distribution equality for subgroups was defined by positive and negative biomarker status. CI, confidence interval.
Fig. 3. Biomarker status for the three biomarkers, at primary diagnosis and at recurrence/metastasis, for the analysis population.
**Fig. 4.** Conversion/conservation of biomarker status.